Stockscreener 앱 받기
5.01
3.30%
0.16
전일 마감가:
$4.85
열려 있는:
$4.87
하루 거래량:
1.73M
Relative Volume:
0.68
시가총액:
$447.63M
수익:
-
순이익/손실:
$-48.17M
주가수익비율:
-8.7895
EPS:
-0.57
순현금흐름:
$-37.10M
1주 성능:
+17.06%
1개월 성능:
+24.63%
6개월 성능:
-55.51%
1년 성능:
-50.64%
1일 변동 폭
$4.729
$5.19
1주일 범위
$4.11
$5.19
52주 변동 폭
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
AVXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
5.01 | 433.34M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - Yahoo Finance
Trading Action: Can Anavex Life Sciences Corp weather a recessionDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Returns Recap: Why Anavex Life Sciences Corp. stock could rally in 2025Market Risk Report & Momentum Based Trading Ideas - Bộ Nội Vụ
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Anavex Life Sciences
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Eastern Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - Eastern Progress
Why Anavex Life Sciences Corp. stock could rally in 2025Portfolio Update Report & Free Community Consensus Stock Picks - Улправда
Will Anavex Life Sciences Corp. stock continue upward momentumPortfolio Gains Summary & Technical Pattern Recognition Alerts - Улправда
Franklin Credit Management CorporationAVXL ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - FinancialContent
Anavex Life Sciences Corp. (AVXL) Stock Analysis: A 415% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Is Anavex Life Sciences Corp. stock a buy for dividend growth2025 Major Catalysts & Free Real-Time Volume Trigger Notifications - ulpravda.ru
Anavex Life Sciences Appoints Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology - Quiver Quantitative
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology - Anavex Life Sciences
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
Anavex Shares Surge on Encouraging Regulatory Development - AD HOC NEWS
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program - Anavex Life Sciences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL - Chartmill
Anavex Life Sciences (AVXL) Receives Reaffirmed Buy Rating from D. Boral Capital | AVXL Stock News - GuruFocus
D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. Invited by FDA to Present Alzheimer’s Disease Clinical Trial Results - Quiver Quantitative
FDA takes closer look at experimental Alzheimer’s pill in key meeting - Stock Titan
Analyzing 3 Promising Penny Stocks With Market Caps Over $60M - simplywall.st
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What analysts say about Anavex Life Sciences Corp stockHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - earlytimes.in
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Can Anavex Life Sciences Corp. stock sustain free cash flow growth2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Can Anavex Life Sciences Corp. stock resist market sell offs2025 Valuation Update & Weekly Watchlist for Consistent Profits - DonanımHaber
Rate Cut: Why Anavex Life Sciences Corp stock could be next big winner2025 Trading Volume Trends & Accurate Buy Signal Notifications - moha.gov.vn
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's. Read more here. - Seeking Alpha
Anavex Life Sciences Requests European Medicines Agency to Re-evaluate Blarcamesine as Early Alzheimer's Treatment - marketscreener.com
What catalysts could drive Anavex Life Sciences Corp. stock higher2025 Institutional Moves & Technical Pattern Recognition Alerts - Улправда
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion - The Manila Times
Anavex Life Sciences requests EMA to re-examine blarcamesine for Alzheimer's - marketscreener.com
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anavex Life Sciences Corporation 주식 (AVXL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
4.73%
0.92%
자본화:
|
볼륨(24시간):